Prenatal anti-Ro antibody exposure, congenital complete atrioventricular heart block, and high-dose steroid therapy: impact on neurocognitive outcome in school-age children.
OBJECTIVE
To determine the impact of prenatal exposure to maternal anti-Ro antibodies, slow fetal heart rate, and/or prolonged dexamethasone therapy for immune-mediated congenital atrioventricular heart block (CAVB) on the cognitive and academic performance of these children at school age.


METHODS
We performed a prospective, blinded assessment of the cognitive functioning of 3 cohorts of children ages 6-16 years with in utero exposure to maternal anti-Ro antibodies in the following groups: no CAVB and no prenatal dexamethasone treatment (n = 14), CAVB without prenatal treatment (n = 10), and CAVB with prenatal dexamethasone treatment (n = 16). Domains assessed included intelligence, visual perceptual and visual motor skills, auditory and visual attention, verbal learning and memory, visual memory, executive function, and behavior.


RESULTS
All cohorts scored within the normal range and were not significantly different in terms of intelligence scores, verbal comprehension, perceptional reasoning, working memory, and processing speed. For children with CAVB who were treated prenatally, there were no significant associations between the neurocognitive function scores, the minimal fetal heart rate (range 47-80 beats per minute), and either the duration (range 2-15 weeks) or dosage (range 56-824 mg) of dexamethasone therapy.


CONCLUSIONS
CAVB and transplacental treatment with dexamethasone was not associated with neurocognitive impairment in school-age children. Larger numbers of children are needed to validate our observation, and assessment of other cognitive abilities is warranted.
Mount Sinai Hospital, Toronto, Ontario, Canada.
E N
EN
Kelly
R
R
Sananes
C
C
Chiu-Man
E D
ED
Silverman
E
E
Jaeggi
D000293:Adolescent; D000974:Antibodies, Antinuclear / Q000276:immunology*; D002648:Child; D002657:Child Development; D003907:Dexamethasone / Q000008:administration & dosage*; D005260:Female; D005333:Fetus / Q000276:immunology / Q000503:physiopathology; D005938:Glucocorticoids / Q000008:administration & dosage*; D006327:Heart Block / Q000151:congenital* / Q000188:drug therapy; D006340:Heart Rate, Fetal; D006801:Humans; D008297:Male; D009483:Neuropsychological Tests; D011247:Pregnancy; D011297:Prenatal Exposure Delayed Effects / Q000276:immunology; D011446:Prospective Studies; D016896:Treatment Outcome
D000974:Antibodies, Antinuclear; D005938:Glucocorticoids; C035356:SS-A antibodies; D003907:Dexamethasone